Cedo Reveals Roadmap for Sustainable Business Growth
Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/
Cedo CEO, Rik De Vos, says “Cedo is proud of our contribution to achieving the goals of sustainable business development outlined by the UN” (Photo: Business Wire)
“Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transformation, while articulating and communicating proactively and transparently. A dream has been turned into a great journey and it pleases me enormously to see the response from everybody on our ambition.”
People
To better serve customers and employees, Cedo is committing to become positively involved in its communities in the seven countries in which it operates, investing in them both as an employer and community member while actively supporting local environmental, health and wellness projects.
With its industry-leading focus on sustainability and rewarding career and development opportunities, Cedo hopes to attract fresh and diverse talent to join its two thousand-strong workforce who are as committed to environmental sustainability as they are to innovation. “We recognise that our economic growth as a business can only be delivered by valued colleagues and communities, high quality products and a healthy planet. Our pillars are aligned to these beliefs. Real success can only come from delivering progress in all three areas,” De Vos said.
Planet
For planet, the business has committed to achieving climate neutrality across its global operations by 2030, increasing its use of renewable energy and improving energy efficiency usage.
Cedo will also improve its stewardship of water, with clear monitoring and improvement plans while reducing the overall water consumption in its operations. The business aims to send zero waste to landfill and has already achieved this target this year in the UK.
Product
To achieve circularity, Cedo has pledged to use only recycled, recyclable or sustainable materials for both packaging and product design. “We will use the Ellen MacArthur Foundation’s Circulytics measurement tool, transparently tracking its progress to become a circular business,” says Ton Emans, Director of Recycling at Cedo and President of Plastics Recyclers Europe. “We’ve been members of the Ellen MacArthur Foundation and participants of the New Plastics Economy initiative since its inception in 2016 and by working together we are confident that we can transition from a linear to a circular business model over the next few years.”
Working with customers in 34 countries and listening to their needs, Cedo is aiming to dramatically reduce plastics in its products and focus better on the use of raw materials through its eco-design process, selecting the appropriate raw material for each product and its intended life cycle. Going forward, the business will only purchase from suppliers which meet its ethical, environmental and social standards.
All of these steps that Cedo is taking towards sustainable business growth will be measured and shared in a new, fully transparent Grow With Purpose report, released every year.
Supporting nine of the United Nations Sustainable Development Goals
As well as outlining its approach to doing business, Cedo’s Roadmap for Sustainable Business Growth explains how it will work towards nine of the United Nations Sustainable Development Goals. These are Goal 3, Good Health and Well-Being; Goal 5, Gender Equality; Goal 8, Decent Work and Economic Growth; Goal 9, Industry, Innovation and Infrastructure; Goal 12, Responsible Consumption and Production; Goal 13, Climate Action; Goal 14, Life Below Water; Goal 15, Life On Land and Goal 16, Peace, Justice and Strong Institutions.
In July 2021, Cedo announced that it is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005048/en/
Contact information
For further information please contact Miki Haines-Sanger on +44 7900 690 574 / miki@goldengoosepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
